Drug Evaluation
Bilastine for the treatment of urticaria
Posted online on May 16, 2013.
(doi:10.1517/14656566.2013.800044)
Ignacio Jáuregui †1, Marta Ferrer 2, Joan Bartra 3, Alfonso del Cuvillo 4, Ignacio Dávila 5, Javier Montoro 6, Joaquim Mullol 7, Joaquín Sastre 8, Antonio Valero 3
1 Servicio de Alergia, Hospital Universitario Basurto, Hospital de Basurto, Avenida de Montevideo,
18 -48013 Bilbao
, Spain ignacio.jaureguipresa@osakidetza.net
2 Servicio de Alergia, Clínica Universitaria,
Pamplona
, Spain
3 Unitat d'Al·lèrgia, Servei de Pneumologia i Al·lèrgia Respiratòria, Hospital Clínic (ICT),
Barcelona
, Spain
4 Clínica Dr. Lobatón,
Cádiz
, Spain
5 Servicio de Inmunoalergia, Complejo Asistencial Universitario de Salamanca, IBSAL,
Salamanca
, Spain
6 Unidad
de Alergia, Hospital Universitario Arnau de Vilanova, Facultad de
Medicina, Universidad Católica de Valencia, ‘San Vicente Mártir',
Valencia
, Spain
7 Unitat de Rinologia i Clínica de l'Olfacte, Servei d'Otorinolaringologia, Hospital Clínic (ICT),
Barcelona
, Spain
8 Servicio de Alergia, Fundación Jiménez Díaz,
Madrid
, Spain
Introduction:
Urticaria is a highly prevalent disease among people. First-choice
treatment continues to be centred on the second-generation H1
antihistamines, including a wide group of drugs with a better
therapeutic index (or risk:benefit ratio) than the classic ones, even in
the high, off-label dosage occasionally required in chronic urticaria. Bilastine
is a newly registered H1-antihistamine for treatment of allergic
rhinoconjunctivitis and urticaria. With established antihistaminic and
antiallergic properties, it is widely reviewed in the medical
literature; however, to our knowledge, a specific review of bilastine's
role in the treatment of urticaria was lacking.
Areas covered:
This article reviews the medical literature on the effectiveness and
safety of bilastine in urticarial syndromes, either spontaneous or
inducible, by means of a Medline search from 1990 to present, completed
with some nonpublished data provided by the manufacturer.
Expert opinion:
Once-daily treatment with bilastine 20 mg is effective in managing
symptoms and improving patient's quality of life in chronic urticaria,
with at least comparable efficacy to levocetirizine. As far as studies
in healthy volunteers, clinical assays, and recent clinical experience
can establish, bilastine's safety profile is adequate, appearing to be
entirely free from cardiovascular effects, and not impairing psychomotor
performance or actual driving, even at twice the therapeutic dose.
Read More: http://informahealthcare.com/doi/abs/10.1517/14656566.2013.800044
No hay comentarios.:
Publicar un comentario
Write here your comment